Anabolic and Emerging Therapies

To date conventional osteoporosis therapy has been largely dominated by the use of anti-resorptive therapy but more recently anabolic agents have emerged as an important option for bone health management. Teriparatide is the most well-known anabolic agent. Its efficacy with regard to bone mineral density increase and fracture reduction have been demonstrated in numerous studies while abaloparatide has been licenced in the United States for osteoporosis management. In the last year, a new therapeutic target, romosozumab, an anti-sclerostin monoclonal antibody, achieved approval in both Europe and the United States, for management of osteoporosis. This provides an overview of current and emerging potential therapeutic targets.